Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 8/20 | 0.84 |
| ▸ | BTK | Q06187 | 11/20 | 0.79 |
| ▸ | LCK | P06239 | 7/20 | 0.68 |
| ▸ | BRAF | P15056 | 2/20 | 0.67 |
| ▸ | JAK2 | O60674 | 1/20 | 0.67 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.67 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.67 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.67 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.67 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.67 |
| ▸ | BLK | P51451 | 2/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2494867 | 0.92 | CSF1R (0.70) | CSF1RBTKLCKBRAFJAK2 | |
| SCHEMBL2497726 | 0.92 | BTK (0.83) | CSF1RBTKLCKBRAFJAK2 | |
| SCHEMBL1276893 | 0.92 | CSF1R (1.00) | CSF1RBTKBRAFJAK2PDGFRB | |
| SCHEMBL2496610 | 0.89 | BTK (0.86) | CSF1RBTKLCKBRAFMAPK14 | |
| SCHEMBL2493840 | 0.89 | BTK (0.79) | CSF1RBTKLCKBRAFJAK2 | |
| SCHEMBL2495621 | 0.88 | BTK (0.75) | CSF1RBTKLCKBRAFJAK2 | |
| SCHEMBL15998211 | 0.88 | BTK (1.00) | CSF1RBTKLCKBRAFJAK2 | |
| SCHEMBL2501240 | 0.87 | CSF1R (0.69) | CSF1RBTKLCKBRAF | |
| SCHEMBL15998163 | 0.86 | BTK (0.81) | CSF1RBTKLCKBRAFJAK2 | |
| SCHEMBL2494865 | 0.86 | CSF1R (0.65) | CSF1RBTKLCKBRAFJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8030487-B2 | 2-amino—5-substituted pyrimidine inhibitors | TARGEGEN, INC. (US) | 2011-10-04 | — | — | US | disclosed |
| US-8030487-B2 | 2-amino—5-substituted pyrimidine inhibitors | TARGEGEN, INC. (US) | 2011-10-04 | — | — | US | disclosed |
| US-8030487-B2 | 2-amino—5-substituted pyrimidine inhibitors | TARGEGEN, INC. (US) | 2011-10-04 | — | — | US | disclosed |
| US-20080027070-A1 | 2-AMINO--5-SUBSTITUTED PYRIMIDINE INHIBITORS | TARGEGEN, INC. (US) | 2008-01-31 | — | — | US | disclosed |
| US-20080027070-A1 | 2-AMINO--5-SUBSTITUTED PYRIMIDINE INHIBITORS | TARGEGEN, INC. (US) | 2008-01-31 | — | — | US | disclosed |
| US-20080027070-A1 | 2-AMINO--5-SUBSTITUTED PYRIMIDINE INHIBITORS | TARGEGEN, INC. (US) | 2008-01-31 | — | — | US | disclosed |
| WO-2008008234-A1 | 2-AMINO-5-SUBSTITUTED PYRIMIDINE INHIBITORS | TARGEGEN, INC. (US) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027070-A1 | 2-AMINO--5-SUBSTITUTED PYRIMIDINE INHIBITORS | KDR, FLT4, FLT1 | CSF1R 575/4885BTK 44/4885LCK 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.